Boston Scientific has announced that it has entered into a definitive agreement to acquire Preventice Solutions, a developer of mobile health and remote monitoring technology for patients with cardiac arrhythmias.

The deal includes an upfront payment of $925 million along with a provision for up to $300 million in additional milestone payments. The acquisition is expected to close by mid-2021.

Preventice offers wearable cardiac monitoring products, including the PatientCare platform and BodyGuardian monitors. The BodyGuardian monitors use a cloud-based platform and an independent diagnostic testing facility to support diagnosis of cardiac arrhythmias.